Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?

Abirramy Varatharajan; Timothée Olivier; Vinay Prasad

doi:10.1016/j.eururo.2023.01.024

Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?

Eur Urol. 2023 Jun;83(6):481-483. doi: 10.1016/j.eururo.2023.01.024. Epub 2023 Feb 10.

Authors

Abirramy Varatharajan¹, Timothée Olivier², Vinay Prasad³

Affiliations

¹ Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: abirramy12@gmail.com.
² Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
³ Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA.

PMID: 36774222
DOI: 10.1016/j.eururo.2023.01.024

Abstract

Higher diagnostic accuracy, even if desirable, is not automatically associated with better outcomes. If used in settings validated with less sensitive imaging modalities, it is of paramount importance to prospectively ascertain that the higher sensitivity of prostate-specific antigen membrane-based imaging will benefit patients, and will probably not do harm.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Gallium Radioisotopes
Humans
Male
Neoplasm Staging
Positron Emission Tomography Computed Tomography / methods
Positron-Emission Tomography / methods
Prostate* / pathology
Prostate-Specific Antigen
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / pathology

Substances

Prostate-Specific Antigen
Gallium Radioisotopes